Xilio Therapeutics (XLO) Income from Continuing Operations (2020 - 2026)
Xilio Therapeutics (XLO) posted Income from Continuing Operations of 14131000.0 for Q1 2026, down 19.12% sequentially from 11863000.0 in Q4 2025, and down 1.59% YoY from 14359135.8 in Q1 2025.
Xilio Therapeutics (XLO) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Xilio Therapeutics has reported Income from Continuing Operations for 7 years, with the latest figure at 14131000.0 in Q1 2026.
- Quarterly Income from Continuing Operations fell 1.59% year-over-year to 14131000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 42396000.0 (up 26.35% YoY) and the FY2025 annual result came in at 167419000.0, up 3.28% from the prior year.
- Income from Continuing Operations retreated to 14131000.0 in Q1 2026 per XLO's latest filing, from 11863000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 1997000.0 in Q3 2025 and troughed at 24825000.0 in Q2 2022.
- A 5-year average of 16973000.0 and a median of 17404000.0 in 2023 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2022 and 2025: Income from Continuing Operations slipped 28.13% in 2022, then surged 86.56% in 2025.
- Over 5 years, Income from Continuing Operations stood at 24421000.0 in 2022, then rose by 24.84% to 18356000.0 in 2023, then gained by 24.22% to 13911000.0 in 2024, then rose by 14.72% to 11863000.0 in 2025, then slipped by 19.12% to 14131000.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 14131000.0, 11863000.0, and 1997000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Xilio Therapeutics | 178.33 Mn | 42.29 Mn | - | -3.49 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3.62 Mn |
| Mar 31, 2026 | -14.13 Mn |
| Dec 31, 2025 | -11.86 Mn |
| Sep 30, 2025 | -2.00 Mn |
| Jun 30, 2025 | -14.41 Mn |
| Mar 31, 2025 | -13.91 Mn |
| Dec 31, 2024 | -13.91 Mn |
| Sep 30, 2024 | -14.86 Mn |
| Jun 30, 2024 | -14.88 Mn |
| Mar 31, 2024 | -17.80 Mn |
| Dec 31, 2023 | -18.36 Mn |
| Sep 30, 2023 | -17.40 Mn |
| Jun 30, 2023 | -20.19 Mn |
| Mar 31, 2023 | -23.74 Mn |
| Dec 31, 2022 | -24.42 Mn |
| Sep 30, 2022 | -20.43 Mn |
| Jun 30, 2022 | -24.83 Mn |
| Mar 31, 2022 | -21.42 Mn |
| Dec 31, 2021 | -19.66 Mn |
| Sep 30, 2021 | -31.76 Mn |